Choi Seol Ri (Fictional)

Born:: November 3, 1985, Seoul, South Korea
Nationality:: South Korean-Canadian
Profession(s):: Molecular Biologist, Biotechnologist, Entrepreneur

Early Life and Education

Born in Seoul, South Korea, to parents Ji-Hoon and Mi-Young Choi.
Emigrated to Alberta, Canada, at the age of 10.
Graduated valedictorian from Crescent Heights High School, Calgary.
BSc in Biochemistry, University of Alberta (2007), summa cum laude.
PhD in Molecular Biology, University of California, Berkeley (2012). Dissertation: "Novel Applications of CRISPR-Cas9 in Gene Therapy for Cystic Fibrosis."

Career and Major Achievements

Postdoctoral Fellow, Massachusetts Institute of Technology (MIT), 2012-2014, focusing on gene editing technologies.
Founded "Algen Biopharmaceuticals" in Alberta in 2015, specializing in developing gene therapies for genetic disorders.
2018: Algen Biopharmaceuticals received FDA approval for its gene therapy treatment for a rare form of muscular dystrophy.
2020: Recognized as one of "Canada's Top 40 Under 40" for contributions to biotechnology.
2023: Algen Biopharmaceuticals acquired by a major pharmaceutical company for $1 billion CAD.

Notable Works

Patents

US Patent 9,873,872 B2: "Novel CRISPR-Cas9 Delivery System for Gene Therapy."
Canadian Patent CA 2948273 A1: "Targeted Gene Editing for Cystic Fibrosis Treatment."

Publications

Choi, S.R., et al. "Enhanced Gene Editing Efficiency Using Optimized CRISPR-Cas9 Delivery." Nature Biotechnology, 32(5), 2014, 456-462.
Choi, S.R., & Jones, A.B. "Targeted Gene Therapy for Muscular Dystrophy: A Clinical Trial Report." The Lancet, 392(10157), 2018, 1520-1528.

Legacy and Impact

The biography of Choi Seol Ri of Alberta demonstrates the impact of her innovative work in gene therapy, particularly her contribution to developing treatments for previously incurable genetic diseases. Her entrepreneurial success with Algen Biopharmaceuticals has also significantly boosted the biotechnology sector in Alberta, creating jobs and attracting investment.